MESO Mesoblast Ltd
Price (delayed)
$11.1
Market cap
$1.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$1.37B
mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells
Highlights
The quick ratio has shrunk by 78% YoY
Mesoblast's net income has decreased by 41% YoY
Key stats
What are the main financial stats of MESO
Market
Valuations
Earnings
Shares outstanding
115.24M
Market cap
$1.28B
Enterprise value
$1.37B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.75
Price to sales (P/S)
223.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
241.15
Revenue
$5.67M
Gross profit
$5.67M
Operating income
-$50.42M
Net income
-$103.35M
EBIT
-$79.71M
EBITDA
N/A
Free cash flow
-$42.71M
Per share
Balance sheet
Liquidity
EPS
-$0.93
EPS diluted
-$0.93
Free cash flow per share
-$0.37
Book value per share
$4.04
Revenue per share
$0.05
TBVPS
$0.69
Total assets
$653.32M
Total liabilities
$192.06M
Debt
$126.11M
Equity
$461.26M
Working capital
-$3.07M
Debt to equity
0.27
Current ratio
0.96
Quick ratio
0.56
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
100%
Net margin
-1,822.8%
Operating margin
-889.2%
Return on assets
-15.6%
Return on equity
-21.3%
Return on invested capital
-79.5%
Return on capital employed
-13.7%
Return on sales
-1,405.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MESO stock price
How has the Mesoblast stock price performed over time
Intraday
2.21%
1 week
7.66%
1 month
-20.37%
1 year
85%
YTD
-43.94%
QTD
-11.06%
Financial performance
How have Mesoblast's revenue and profit performed over time
Revenue
$5.67M
Gross profit
$5.67M
Operating income
-$50.42M
Net income
-$103.35M
Gross margin
100%
Net margin
-1,822.8%
The net margin has dropped by 86% year-on-year
Mesoblast's net income has decreased by 41% YoY
The company's gross profit fell by 24% YoY
The company's revenue fell by 24% YoY
Growth
What is Mesoblast's growth rate over time
Valuation
What is Mesoblast stock price valuation
P/E
N/A
P/B
2.75
P/S
223.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
241.15
The EPS has decreased by 8% YoY
The stock's P/B is 72% above its 5-year quarterly average of 1.6 and 38% above its last 4 quarters average of 2.0
Mesoblast's equity has decreased by 9% YoY
The stock's price to sales (P/S) is 135% more than its 5-year quarterly average of 95.1 and 45% more than its last 4 quarters average of 154.1
The company's revenue fell by 24% YoY
Efficiency
How efficient is Mesoblast business performance
The ROS has shrunk by 96% YoY
MESO's ROE is down by 47% year-on-year
The ROA has contracted by 43% YoY
MESO's ROIC is down by 39% YoY
Dividends
What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MESO.
Financial health
How did Mesoblast financials performed over time
The quick ratio has shrunk by 78% YoY
MESO's current ratio has dropped by 65% year-on-year
The debt is 73% smaller than the equity
Mesoblast's debt to equity has increased by 13% YoY
Mesoblast's equity has decreased by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.